Insmed Shares Latest Clinical and Business Developments
Insmed's Phase 2b trial of brensocatib in CRSsNP did not meet efficacy endpoints, leading to discontinuation of that program, but the company acquired a promising monoclonal antibody, INS1148, for respiratory and inflammatory diseases, expanding its pipeline.